FDA Issues Reminder of Non-Substitution of PEDMARK® (sodium thiosulfate injection) for Pediatric Patients Receiving Cisplatin

RESEARCH TRIANGLE PARK, N.C., Feb. 01, 2024 -- Fennec Pharmaceuticals Inc. , a commercial stage specialty pharmaceutical company, today announced that the U.S. Food and Drug Administration has...

Related Keywords

Oregon ,United States ,Lindsay Rocco ,Robert Andrade ,Oregon Health ,Office Of Communications ,Science University ,Elixir Health Public Relations ,Nasdaq ,Fennec Pharmaceuticals ,Fennec Pharmaceuticals Inc ,Drug Administration ,Stakeholder Engagement Staff ,Drug Evaluation ,European Commission Marketing Authorization ,Orphan Drug Exclusivity ,Pediatric Use Marketing Authorization ,Markets ,